Founded in 2003, Marinus Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company located in Branford, Connecticut. Marinus is dedicated to the reformulation, development, and commercialization of Ganaxolone (Trade name Ztalmy®). In Q1 2022 Ztalmy® received an approval from US Food and Drug Administration (FDA).
ZTALMY® is a prescription medicine used to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in people 2 years of age and older. It is not known if ZTALMY is safe and effective in children under 2 years of age. ZTALMY is a sugar-free cherry-flavored oral suspension suitable for ketogenic diets.
Clinical studies are ongoing on the use of the drug for the treatment of other similar diseases.
Please visit www.ztalmy.com for detailed information on the product.